X4P-001-IO in Oncology
X4P-001-IO is part of a new wave of cancer therapies that tap into the power of a patient’s own immune system to fight cancer. X4P-001-IO is a CXCR4 inhibitor that is being investigated in Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC), melanoma, and other solid tumors. These cancers are aggressive and tend to break through treatment.
Dysregulation of the CXCR4-CXCL12 axis plays a critical role in promoting pro-tumor effects (tumor cell migration and invasion, angiogenesis, resistance, immune cell evasion) that define multiple advanced cancers. X4P-001-IO is designed to block the CXCR4/CXCL12 pathway to create an anti-tumor immune response and block angiogenic signaling within the tumor microenvironment.
In multiple preclinical models of cancer, X4P-001-IO significantly reduced tumor growth and increased overall survival, both as a single agent and when used in combination with approved anti-cancer agents, including immunotherapies, tyrosine kinase inhibitors, and chemotherapy.